Fintel reports that on June 26, 2025, UBS downgraded their outlook for CureVac N.V. (NasdaqGM:CVAC) from Buy to Neutral.

TÜBINGEN, GERMANY AND BOSTON, MA / ACCESS Newswire / June 24, 2025 / CureVac N.V. (NASDAQ:CVAC), a pioneering multinational ...

BioNTech has announced the acquisition of fellow German biotech CureVac in an all-stock transaction valued at approximately $1.25 billion. Under the agreement, CureVac shareholders will receive about ...

German biotech firm BioNTech has agreed to acquire domestic peer CureVac for about $1.25 billion worth of BioNTech shares, it said on Thursday, to boost its work on new mRNA-based cancer treatments.

CureVac shares skyrocketed 35% Thursday when the biotech firm agreed to be bought by COVID-19 vaccine maker BioNTech in an all-stock deal valued at about $1.25 billion.

CureVac Announces Voting Results of General Meeting TÜBINGEN, Germany / BOSTON, USA - June 24, 2025 - CureVac N.V. (Nasdaq: ...

U.S. equities were mixed and little changed at midday as a second inflation report this week came in lower than anticipated.

BioNTech and CureVac expect the acquisition will close later this year. Afterward, CureVac will operate as a wholly owned subsidiary with its manufacturing site in Tübingen integrated into BioNTech.

CureVac is leveraging mRNA technology, combined with advanced omics and computational tools, to design and develop off-the-shelf and personalized cancer vaccine product candidates.

Shares of CureVac N.V. CVAC have skyrocketed 40.8% in a month after the company signed a definitive agreement to be acquired by BioNTech SE BNTX in an all-stock transaction last week. Per the ...